Member Info for Krone

We have plenty of evidence that Sareum potentially has world beating products. What we lack is any evidence that the BoD has the commercial nous to realise the value of the assets or effectively manage PR.

The announcement regarding the Aurora FLT3 licence refers to certain small molecule inhibitors/compounds i.e. plural. Do we know how many potential drugs could come out of this deal?

'Under the terms of the Agreement, the Licensee has been granted an exclusive worldwide licence to develop, manufacture and commercialise certain small molecule inhibitors of FLT3+Aurora kinases including Sareum’s lead candidate SAR-20293 (together the “Compounds”), which has shown potential in preclinical models of acute myeloid leukaemia (AML) and other leukaemias.
http://www.sareum.com/news/press-releases-and-news/2020/global-licensing-flt3auroa-programme/

Thanks Potnak, so we can reasonably expect an RNS in the very near future!

Thanks Potnak, really the question was around if/when does the bod have to inform shareholders that we have been successful in obtaining a grant?

At what point are the BoD formally required to inform investors that we have been awarded a grant to progress SDC-1801.
Thoth2 - Referring to one of your previous posts re proof of concept, would the data from the SRI lupus study not go a long way in this regard and shorten the timescales for poc I.r.o Covid19?

...However, some experts believe there could be another solution: finding a way to reduce the acute inflammation in the lungs which leads to the creation of sticky blood, the source of the problem. Sareum Holdings, come on down......

Coronavirus: A third of hospital patients develop dangerous blood clots https://www.bbc.co.uk/news/health-52662065

?

Further context: https://endpts.com/covid-19-roundup-trump-administration-prepping-exec-order-to-reduce-reliance-on-foreign-manufacturing-of-essential-medicines/

Thanks RMM, excellent post. Given Trump’s erratic and predictable unpredictability would you not think there is a risk in going with the Chinese. On a whim Trump could prevent Chinese pharmaceutical imports even if in doing so he would be cutting of his nose.....

Hi Fadec/Thoth2 - have you seen: Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1
https://www.sciencedirect.com/science/article/abs/pii/S0968089620303011?via%3Dihub#ab010

Hi BoilB - don’t think so, the licence is between ICR/CRT and Sierra. Anyone else know?

https://twitter.com/sierraoncology/status/1260953069904367618?s=21
It’ll be interesting to see how many takers sign up to the trial in the current circumstances.

Glover is throwing everything including the kitchen sink at momelotinib having previously been extolling SRA737 as the best thing since sliced bread. SRA737 is now in the long grass despite data indicating that it is efficacious in areas on unmet clinical need.

http://investor.sierraoncology.com/2020-05-14-Sierra-Oncology-to-Report-Favorable-Dose-Intensity-Data-and-Long-Term-Safety-Data-for-Momelotinib-at-the-25th-European-Hematology-Association-EHA-Congress

RMM - excellent, love it! We have spuds coming up from 2 years ago!

Hi Stockfield, I would agree with your take on this. It seemed clear from what Tim/John said/didn’t say that the data were being shared as necessary.

Thoth - thanks.

PS....Bearing in mind we already have the SRI DoD unpublished data.

There’ll be no dilly dallying on this...what is the realistically shortest time we could get from poc to phase 1 trials?

Do we know if 1801 can be administered IV as well as orally given that an apparently significant number of patients requiring treatment will be unconscious and being ventilated.